Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00130026 · ClinicalTrials.gov registry record · NA

Caffeine in the Prevention of Post-operative Nausea and Vomiting

A NA study, sponsored by Beth Israel Deaconess Medical Center.

Completed
Registry status
NA
Development phase
135
Enrollment target

NCT00130026: Completed NA study, sponsored by Beth Israel Deaconess Medical Center.

NCT00130026 is a NA study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 135 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00130026, a NA study, has completed, sponsored by Beth Israel Deaconess Medical Center.

COMPLETED
Registry status
NA
Development phase
135 participants
Enrollment target

Study Summary

The objective of this study is to determine if caffeine 500 mg intravenously is efficacious when added to standard anti-emetic prophylaxis in the prevention of post-operative nausea and vomiting (PONV) in patients undergoing ambulatory surgery under general anesthesia.

Interventions

  • DRUG Caffeine

Trial Details

FieldValue
Enrollment Target 135 participants
Start Date 2005-03
Est. Completion 2005-10
Phase NA

What the finished NCT00130026 record still lists

NCT00130026 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).

The record links to 0 conditions, and to 1 intervention - of which Caffeine is the first listed.

NCT00130026 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00130026 about?

NCT00130026 is a clinical study titled "Caffeine in the Prevention of Post-operative Nausea and Vomiting". The objective of this study is to determine if caffeine 500 mg intravenously is efficacious when added to standard anti-emetic prophylaxis in the prevention of post-operative nausea and vomiting (PONV) in patients undergoing ambulatory surgery under general anesthesia.

What is the current status of trial NCT00130026?

This trial is currently completed. It is a NA study. The enrollment target is 135 participants. The study started on 2005-03. Estimated completion is 2005-10.

What interventions are being tested in trial NCT00130026?

The interventions under investigation include: Caffeine (DRUG).

Who is sponsoring clinical trial NCT00130026?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00130026's enrollment target sits among peer trials

135 726th of 2000 higher than 1,273 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00870129 · 135 participants · NA

    Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors

  • NCT03666000 · 135 participants · Phase 1

    Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • NCT04891510 · 135 participants · NA

    A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery

  • NCT05121051 · 135 participants · Phase 2

    Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00130026, the US trial registry maintained by the National Library of Medicine. NCT00130026 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.